1. Approach to MPN Symptom Assessment

   • Holly Geyer
   • Ruben A. Mesa

   Myeloproliferative Neoplasms (B Stein, Section Editor) 23 September 2017 Pages: 381 - 388

   

2. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis

   • Karlyn Martin

   Myeloproliferative Neoplasms (B Stein, Section Editor) 25 September 2017 Pages: 389 - 396

3. Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature

   • Amy Zhou
   • Amber Afzal
   • Stephen T. Oh

   Myeloproliferative Neoplasms (B Stein, Section Editor) 25 September 2017 Pages: 397 - 405

4. Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms

   • Charles Elliott Foucar
   • Brady Lee Stein

   Myeloproliferative Neoplasms (B Stein, Section Editor) 25 September 2017 Pages: 406 - 414

   

5. Chronic Myeloid Leukemia—the Promise of Tyrosine Kinase Inhibitor Discontinuation

   • Ravi Kishore Narra
   • Kathryn E. Flynn
   • Ehab Atallah

   Myeloproliferative Neoplasms (B Stein, Section Editor) 25 September 2017 Pages: 415 - 423

6. Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender

   • Jeffrey Patterson-Fortin
   • Alison R. Moliterno

   Myeloproliferative Neoplasms (B Stein, Section Editor) 25 September 2017 Pages: 424 - 431

   

7. Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

   • Kim-Hien T. Dao
   • Jeffrey W. Tyner
   • Jason Gotlib

   Myeloproliferative Neoplasms (B Stein, Section Editor) 06 October 2017 Pages: 432 - 441

   

8. Familial MPN Predisposition

   • Tsewang Tashi
   • Sabina Swierczek
   • Josef T. Prchal

   Myeloproliferative Neoplasms (B Stein, Section Editor) 13 October 2017 Pages: 442 - 447

   

9. Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics

   • Aaron C. Shaver
   • Adam C. Seegmiller

   Myelodysplastic Syndromes (M Savona, Section Editor) 18 August 2017 Pages: 448 - 454

   

10. Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times

    • Sagar S. Patel
    • Aaron T. Gerds

    Myelodysplastic Syndromes (M Savona, Section Editor) 18 August 2017 Pages: 455 - 460

11. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS

    • Aziz Nazha
    • Rafael Bejar

    Myelodysplastic Syndromes (M Savona, Section Editor) 26 August 2017 Pages: 461 - 467

    

12. Therapy for Chronic Myelomonocytic Leukemia in a New Era

    • Tamara K. Moyo
    • Michael R. Savona

    Myelodysplastic Syndromes (M Savona, Section Editor) 06 October 2017 Pages: 468 - 477

    

13. Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes

    • Leylah M. Drusbosky
    • Christopher R. Cogle

    Myelodysplastic Syndromes (M Savona, Section Editor) Open access 14 September 2017 Pages: 478 - 483

    

14. Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies

    • Lorenzo Falchi

    CART and Immunotherapy (M Ruella, Section Editor) 18 August 2017 Pages: 484 - 494

15. Minimal Residual Disease Eradication in CML: Does It Really Matter?

    • Srinivas K. Tantravahi
    • Raga S. Guthula
    • Michael W. Deininger

    Chronic Myeloid Leukemias (J Pinilla-Ibarz, Section Editor) 29 August 2017 Pages: 495 - 505